Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus ‐associated oropharyngeal squamous cell cancer

ConclusionAfatinib, ribavirin, paclitaxel, and carboplatin induction chemotherapy is safe and well tolerated. The phase II recommended dose of afatinib is 40 mg oral daily in this combination regimen.

Source: Head and Neck - September 30, 2017 Category: ENT & OMF Authors: Lara A. Dunn, Matthew G. Fury, Eric J. Sherman, Alan A. Ho, Nora Katabi, Sofia S. Haque, David G. Pfister Tags: ORIGINAL ARTICLE Source Type: research